Načítá se...
Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer†
OBJECTIVES: Neoadjuvant therapy has emerged as a favoured treatment paradigm for patients with clinical N2 disease undergoing surgical resection for non-small-cell lung cancer. It is unclear whether such a treatment paradigm affects perioperative outcomes. We sought to examine the National Cancer Da...
Uloženo v:
| Vydáno v: | Eur J Cardiothorac Surg |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6018932/ https://ncbi.nlm.nih.gov/pubmed/29253122 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ejcts/ezx406 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|